Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds

Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Biomed Res Int
Prif Awduron: Giudice, Giuseppe, Filoni, Angela, Maggio, Giulio, Bonamonte, Domenico, Vestita, Michelangelo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Hindawi Publishing Corporation 2017
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5331316/
https://ncbi.nlm.nih.gov/pubmed/28293640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/9567498
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg